SERB Pharmaceuticals and Y-mAbs Therapeutics, Inc. have entered into a definitive merger agreement under which SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA®.

– Phase 3 trial achieved primary endpoint, quickly and safely restoring platelet function in ticagrelor-treated patients undergoing urgent surgery or experiencing major bleeding  – Results presented today in Late-Breaking Clinical Trial Session at the American College of Cardiology Annual Scientific Session  SFJ Pharmaceuticals (SFJ) and SERB Pharmaceuticals (SERB) announced today the final results of the pivotal […]

SERB Pharmaceuticals (SERB) announces the publication of the largest and most comprehensive study to date of patients with high-dose methotrexate (MTX)- induced acute kidney injury (MTX-AKI) treated with and without Voraxaze® (glucarpidase).